Stocks · News reference

Grainger plc Announces Topping Out of Alloy Apartments in Guildford

2026-11-02 09:01:37 UTC

Grainger plc has reached a construction milestone at its Alloy Apartments development in Guildford, part of a £75 million project expected to deliver 179 rental homes.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GRI

Source: fiscal.ai
Observed: 2026-11-02 09:01:37 UTC
Checked: 2026-11-02 09:02:20 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

SEC EDGAR2026-11-04 22:12:58 UTCSEC EDGAR
8-K filing — GRI Bio, Inc. (GRI)
Filed: 2026-11-04 AccNo: 0001824293-26-000063 Size: 311 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
GRI
Benzinga2026-09-14 15:47:50 UTCBenzinga News-desk
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
https://www.zacks.com/stock/news/2989341/gri-bio-inc-gri-upgraded-to-buy-what-does-it-mean-for-the-stock
GRI
Benzinga2026-09-10 17:24:32 UTCBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates GRI Bio (NASDAQ:GRI) with a Buy and maintains $10 price target.
GRI
Benzinga2026-09-08 14:29:15 UTCBenzinga Newsdesk
GRI Bio shares are trading lower after the company announced new translational biomarker data from the Phase 2a GRI-0621-IPF-02 study evaluating GRI-0621 in patients with idiopathic pulmonary fibrosis.
GRI
Benzinga2026-09-08 12:17:26 UTCBenzinga Newsdesk
GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study
GRI
Benzinga2026-08-24 14:36:57 UTCBenzinga Newsdesk
GRI Bio shares are trading higher after the company announced three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at ERS Congress 2026.
GRI

Grainger plc Announces Topping Out of Alloy Apartments in Guildford

Connected Markets

Related Headlines

8-K filing — GRI Bio, Inc. (GRI)

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target

GRI Bio shares are trading lower after the company announced new translational biomarker data from the Phase 2a GRI-0621-IPF-02 study evaluating GRI-0621 in patients with idiopathic pulmonary fibrosis.

GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study

GRI Bio shares are trading higher after the company announced three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at ERS Congress 2026.